Second-Line CART T-Cell Therapy for Multiple Myeloma - Advanced Practitioner Society for Hematology and Oncology

Second-Line CAR T-Cell Therapy for Multiple Myeloma

In this Educator Module, Michelle Lauer, PA-C, MPH, of Stanford Health Care, provides a comprehensive overview of the CARTITUDE-4 study data, which led to FDA approval of ciltacabtagene autoleucel in the second line for patients with relapsed/refractory multiple myeloma. Ms. Lauer discusses appropriate identification of good candidates for second-line CAR T-cell therapy, barriers to treatment, and incidence and management of associated toxicities.

Funding and support provided by Johnson & Johnson and Legend Biotech.

Download

  Powerpoint (.ppt)
  Presentation Notes (.pdf)
  Listen to Audio Narration Only (.mp3)

Meet The Faculty

Michelle Lauer, PA-C, MPH
Stanford Healthcare

Michelle Lauer is a physician assistant at Stanford Healthcare in Palo Alto, California. She completed her PA studies at Arcadia University in Glenside, Pennsylvania, in 2016. Since then, she has worked at multiple academic medical centers to help care for patients with hematologic malignancies undergoing chemotherapy, transplant, and immunotherapy treatment. She currently works in the Bone Marrow Transplantation and Cell Therapy Division at Stanford.

Sarah Jimenez, DNP, AGACNP-BC, AOCNP
Georgia Cancer Center
Augusta University

Sarah Jimenez, DNP, AGACNP-BC, AOCNP, has more than 20 years of extensive experience in hematologic malignancies and cellular therapies. Dr. Jimenez is currently part of the Bone Marrow Transplant and Cellular Therapy program and co-director of the Oncology APP Clinical Preceptorship Program at Wellstar MCG Health/Georgia Cancer Center. Dr. Jimenez was awarded the ACS graduate scholarship in Oncology Nursing and has received numerous awards and recognition for her excellence in oncology practice.

Binita Parekh, CRNP, BMTCN
The University of Alabama at Birmingham

Binita Parekh is an acute care nurse practitioner (NP) with a certification in Blood and Marrow Oncology Nursing who has specialized in bone marrow transplant and cellular therapies for over 13 years working as an NP. She took up the role of CAR-T REMS Authorized Representative at UAB hospital with the first commercial CAR-T and continued to serve until 2024. Additionally, she has served as an APP Grand Rounds planner for UAB hospital, adjunct ACNP instructor for UAB School of Nursing, clinical lab instructor at Jefferson Community College, as well as preceptor for NP students and orienteer for new NPs to the UAB BMT program.